# sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19

> **NCT07359482** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 160 (estimated)

## Conditions studied

- Post-COVID
- POST-Covid 19
- Post-COVID Conditions

## Interventions

- **DRUG:** Fluvoxamine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07359482
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07359482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07359482, "sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07359482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*